Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Incobotulinumtoxina Clear all
Recruiting Phase 2 Interventional

Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)

NCT06293300
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
BoNT A
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

NCT04594213
View directory record Official record
Conditions
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Encino, California • Newport Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 2, 2026, 4:08 AM EDT
Withdrawn Phase 2 Interventional

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

NCT01565395
View directory record Official record
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
Incobotulinum Toxin A, placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 2, 2026, 4:08 AM EDT
Recruiting Phase 3 Interventional

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

NCT07018700
View directory record Official record
Conditions
Episodic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
47
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery

NCT01842529
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation, Indications for CABG
Interventions
botulinum toxin injection, 0.9% normal saline injection, Implantable loop recorder
Biological · Device
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 2, 2026, 4:08 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

NCT07122193
View directory record Official record
Conditions
Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors, Membrane Transport Modulators, Molecular Mechanisms of Pharmacological Action, Cholinergic Agents, Neurotransmitter Agents, incobotulinumtoxinA, Botulinum Toxins, Type A
Interventions
NT 201, NT 201 Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
27
States / cities
Scottsdale, Arizona • Encino, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 2, 2026, 4:08 AM EDT
Withdrawn Early Phase 1 Interventional

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

NCT01520441
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Interventions
BOTOX
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 4 Interventional

Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients

NCT01968902
View directory record Official record
Conditions
Muscle Spasticity, Multiple Sclerosis
Interventions
incabotulinumtoxinA, Placebo
Biological
Lead sponsor
Multiple Sclerosis Center of Northeastern New York
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Latham, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

NCT01653132
View directory record Official record
Conditions
Sialorrhea
Interventions
Incobotulinum Toxin A, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

NCT02002884
View directory record Official record
Conditions
Cerebral Palsy, Spasticity
Interventions
IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 2, 2026, 4:08 AM EDT
Active, not recruiting Phase 2 Interventional

Use of Botulinum Toxin in the Treatment of Androgenic Alopecia

NCT05456087
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
incobotulinumtoxin A
Drug
Lead sponsor
Zel Skin and Laser Specialists
Other
Eligibility
22 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face

NCT05784363
View directory record Official record
Conditions
Enlarged Pores, Sebum Production
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
21 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Coral Gables, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer

NCT02965976
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
Botulinum Toxin Type A, Esophagectomy, Quality-of-Life Assessment
Biological · Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 2, 2026, 4:08 AM EDT
Terminated No phase listed Observational

Longitudinal Evaluation and Real-world Evidence of NT201

NCT05222607
View directory record Official record
Conditions
Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Split-Face Prospective Study Comparing Botox to Xeomin for the Treatment of Facial Wrinkles

NCT02122536
View directory record Official record
Conditions
Facial Wrinkles
Interventions
Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects, Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects
Drug
Lead sponsor
YMD Eye and Face
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

NCT00770211
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Englewood, Colorado • Aventura, Florida • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 2, 2026, 4:08 AM EDT
Terminated Phase 2 Interventional Results available

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

NCT02088632
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Incobotulinumtoxina, Placebo Comparator
Biological · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

NCT04763265
View directory record Official record
Conditions
Frown Lines
Interventions
Botulinum toxin A "BoNT/A-DP", Botulinum toxin A "Botox Cosmetics"
Biological
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Santa Monica, California • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

NCT03985982
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand

NCT02107261
View directory record Official record
Conditions
Dystonia
Interventions
incobotulinumtoxin A, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 2, 2026, 4:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Retrospective Evaluation of Combination Treatment With the Ulthera System

NCT02444169
View directory record Official record
Conditions
Skin Laxity
Interventions
Ultherapy, Incobotulinumtoxin A, Radiesse, Belotero Balance
Device · Drug
Lead sponsor
Ulthera, Inc
Industry
Eligibility
25 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
Laguna Beach, California • San Diego, California • Coral Gables, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatment of Plantar Fasciitis With Xeomin

NCT01678001
View directory record Official record
Conditions
Plantar Fascitis
Interventions
Xeomin
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex

NCT01486264
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Xeomin®
Biological
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 81 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Fountain Valley, California • Loma Linda, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

NCT01931878
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
incobotulinumtoxinA, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 2, 2026, 4:08 AM EDT